Trial Profile
A prospective, Post Marketing Surveillance study to study the safety and effectiveness of omalizumab in Indian patients with Chronic Spontaneous Urticaria refractory to standard of care
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Adverse reactions
- Sponsors Novartis
- 26 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.
- 01 Sep 2016 New trial record